Protara Therapeutics, Inc. financial data

Symbol
TARA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, 3 Rd Floor, New York, NY
Fiscal year end
December 31
Former names
ArTara Therapeutics, Inc. (to 4/23/2020), PROTEON THERAPEUTICS INC (to 12/31/2019)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17K % -18.5%
Debt-to-equity 14.1 % +14%
Return On Equity -56 % +27.4%
Return On Assets -49.1 % +28.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.6M shares +81.5%
Common Stock, Shares, Outstanding 20.6M shares +81.5%
Entity Public Float 18M USD -8.16%
Common Stock, Value, Issued 21K USD +90.9%
Weighted Average Number of Shares Outstanding, Basic 22.3M shares +96.8%
Weighted Average Number of Shares Outstanding, Diluted 22.3M shares +96.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 28.6M USD +21.1%
General and Administrative Expense 17.3M USD -8.81%
Operating Income (Loss) -45.9M USD +36.3%
Nonoperating Income (Expense) 3.84M USD +31.6%
Net Income (Loss) Attributable to Parent -42M USD +39.2%
Earnings Per Share, Basic -2.82 USD/shares +54%
Earnings Per Share, Diluted -2.82 USD/shares +54%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 51.8M USD +53.3%
Marketable Securities, Current 29.7M USD -26.1%
Other Assets, Current 3K USD +50%
Assets, Current 85.1M USD +9.34%
Property, Plant and Equipment, Net 1.11M USD -20.8%
Operating Lease, Right-of-Use Asset 4.51M USD -18.9%
Goodwill 29.5M USD 0%
Other Assets, Noncurrent 33K USD -98.9%
Assets 94.1M USD +6.36%
Accounts Payable, Current 2.3M USD -8.35%
Accrued Liabilities, Current 5.27M USD +59.4%
Liabilities, Current 8.64M USD +27.6%
Operating Lease, Liability, Noncurrent 3.66M USD -22.8%
Liabilities 12.3M USD +6.85%
Accumulated Other Comprehensive Income (Loss), Net of Tax 29K USD
Retained Earnings (Accumulated Deficit) -232M USD -22.1%
Stockholders' Equity Attributable to Parent 81.8M USD +6.28%
Liabilities and Equity 94.1M USD +6.36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD +19.5%
Net Cash Provided by (Used in) Financing Activities -76K USD -18.8%
Net Cash Provided by (Used in) Investing Activities 23.1M USD +134%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 20.6M shares +81.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 52.5M USD +52.1%
Deferred Tax Assets, Valuation Allowance 52.7M USD +35.1%
Deferred Tax Assets, Gross 54.3M USD +34.2%
Operating Lease, Liability 4.74M USD -16.9%
Depreciation 83K USD +7.79%
Payments to Acquire Property, Plant, and Equipment 6K USD -45.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -41.9M USD +38.6%
Lessee, Operating Lease, Liability, to be Paid 5.39M USD -19.8%
Property, Plant and Equipment, Gross 2.12M USD +2.17%
Operating Lease, Liability, Current 1.08M USD +11.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.43M USD +7.69%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4M USD +320%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 654K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD +2.44%
Deferred Tax Assets, Operating Loss Carryforwards 30.7M USD +14.8%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 718K USD -49.8%
Operating Lease, Payments 332K USD 0%
Additional Paid in Capital 314M USD +17.5%
Share-based Payment Arrangement, Expense 4.67M USD -23%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%